<DOC>
	<DOCNO>NCT02183402</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics , safety tolerability digoxin without co-administration BI 1356 . Additionally steady state pharmacokinetics BI 1356 co-administered digoxin determine .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Digoxin With Without Co-administration BI 1356 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Healthy female male accord follow criterion : base upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age ≥ 18 age ≤ 50 year BMI ≥ 18.5 BMI ≤ 29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance GCP local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection ( e.g. , HIV ) History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month less five halflives respective drug prior administration trial Use drug could reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) inability stop alcoholic beverage 24 hour prior dose last sampling time point Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration correct QT interval &gt; 450 m ) A history additional risk factor torsade de pointes ( TdP ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) For female subject : Pregnancy/positive pregnancy test , plan become pregnant study within one month study completion No adequate contraception study one month study completion Lactation period Exclusion criterion specific study : Bradycardia ( &lt; 50/min ) atrioventricular block ( include I grade auriculoventricular ( AV ) block ) screen Creatinine clearance ( CockroftGaultFormula ) &lt; 80 mL/min screen History actual thyroid dysfunction/disease , basal thyroidstimulating hormone ( TSH ) , free triiodothyronine ( FT3 ) , free thyroxine ( FT4 ) normal range screen Any degree hypokalemia , hypomagnesemia , hypercalcemia screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>